Implant: Approved in Australia

Implant: Approved in Australia

( – Implant , Which will release its quarterly earnings on April 20, today announces approval for its Madison Total Knee Transformation by the Therapeutic Products Management (DGA) for marketing in Australia. This approval is part of a distribution agreement concluded with KICo in November 2018 for the commercialization of Madison Prostheses, specifically covering the United States and Australia. The new step includes eight international patents, including the Madison Knee Prosthesis range, FDA 510 (k) approval for marketing in the United States, and C.E. obtained in Europe.

Ludovic Lostennett, Managing Director of Implant, declares: “In line with our strategic plan aimed at opening up new countries, this approval follows the FDA’s approval, as well as the CEO, until May 2024. Achievement of new structural measures for the Group”.

© 2021,

See also  How does Joe Biden's America see the world?

You May Also Like

About the Author: Cory Weinberg

Cory Weinberg covers the intersection of tech and cities. That means digging into how startups and big tech companies are trying to reshape real estate, transportation, urban planning, and travel. Previously, he reported on Bay Area housing and commercial real estate for the San Francisco Business Times. He received a "best young journalist" award from the National Association of Real Estate Editors.

Leave a Reply

Your email address will not be published. Required fields are marked *